BIONTECH SE-ADR (22UA.DE) Stock Price & Overview
FRA:22UA • US09075V1026
Current stock price
The current stock price of 22UA.DE is 77.6 EUR. Today 22UA.DE is down by -0.06%. In the past month the price decreased by -10.6%. In the past year, price decreased by -3.6%.
22UA.DE Key Statistics
- Market Cap
- 18.659B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.70
- Dividend Yield
- N/A
22UA.DE Stock Performance
22UA.DE Stock Chart
22UA.DE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to 22UA.DE. When comparing the yearly performance of all stocks, 22UA.DE is a bad performer in the overall market: 80.06% of all stocks are doing better.
22UA.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to 22UA.DE. While 22UA.DE seems to be doing ok healthwise, there are quite some concerns on its profitability.
22UA.DE Earnings
On March 10, 2026 22UA.DE reported an EPS of -1.25 and a revenue of 907.40M. The company missed EPS expectations (-559.15% surprise) and beat revenue expectations (19.58% surprise).
22UA.DE Forecast & Estimates
28 analysts have analysed 22UA.DE and the average price target is 118.89 EUR. This implies a price increase of 53.21% is expected in the next year compared to the current price of 77.6.
For the next year, analysts expect an EPS growth of 24.94% and a revenue growth -17.91% for 22UA.DE
22UA.DE Groups
Sector & Classification
22UA.DE Financial Highlights
Over the last trailing twelve months 22UA.DE reported a non-GAAP Earnings per Share(EPS) of -4.7. The EPS decreased by -69.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.17% | ||
| ROE | -5.91% | ||
| Debt/Equity | 0.01 |
22UA.DE Ownership
22UA.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 26.73 | 40.051B | ||
| 1AE | ARGENX SE | 26.69 | 39.989B | ||
| 2X1 | ABIVAX SA | N/A | 8.034B | ||
| ABVX | ABIVAX SA | N/A | 8.018B | ||
| GXE | GALAPAGOS NV | N/A | 1.691B | ||
| GLPG | GALAPAGOS NV | N/A | 1.687B | ||
| NANO | NANOBIOTIX | N/A | 1.326B | ||
| 6IV | INVENTIVA SA | N/A | 981.136M | ||
| IVA | INVENTIVA SA | N/A | 980.098M | ||
| PHIL | PHILOGEN SPA | 17.77 | 649.128M | ||
| GNFT | GENFIT | 846.08 | 431.525M | ||
| FYB | FORMYCON AG | N/A | 329.015M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 22UA.DE
Company Profile
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 7,807 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Company Info
IPO: 2019-10-10
BIONTECH SE-ADR
An der Goldgrube 12
Mainz RHEINLAND-PFALZ DE
Employees: 7807
Phone: 4949613190840
BIONTECH SE-ADR / 22UA.DE FAQ
What does BIONTECH SE-ADR do?
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 7,807 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
What is the current price of 22UA stock?
The current stock price of 22UA.DE is 77.6 EUR. The price decreased by -0.06% in the last trading session.
Does 22UA stock pay dividends?
22UA.DE does not pay a dividend.
How is the ChartMill rating for BIONTECH SE-ADR?
22UA.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
On which exchange is 22UA.DE stock listed?
22UA.DE stock is listed on the Frankfurt Stock Exchange exchange.
Can you provide the PE ratio for 22UA stock?
BIONTECH SE-ADR (22UA.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.7).
Who owns BIONTECH SE-ADR?
You can find the ownership structure of BIONTECH SE-ADR (22UA.DE) on the Ownership tab.